Nicotine and cotinine increases the brain penetration of saquinavir in rat

Journal of Neurochemistry

Volumn 115, Issue 6, 2010, Pages 1495-1507

  Manda, Vamshi K ^a   Mittapalli, Rajendar K ^a   Bohn, Kaci A ^a   Adkins, Chris E ^a   Lockman, Paul R ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

blood brain barrier; breast cancer resistance protein; highly active antiretroviral therapy; nicotine; P glycoprotein; protease inhibitors; saquinavir

Indexed keywords

1,2,3,4,6,7,12,12A OCTAHYDRO 6 ISOBUTYL 9 METHOXY 1,4 DIOXOPYRAZINO[1',2':1,6]PYRIDO[3,4 B]INDOLE 3 PROPANOIC ACID TERT BUTYL ESTER; BREAST CANCER RESISTANCE PROTEIN; COTININE; FUROSEMIDE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; NICOTINE; PROBENECID; SAQUINAVIR; SUCROSE; VALSPODAR; VERAPAMIL; VERLUKAST;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; BRAIN PERFUSION; CAUDATE NUCLEUS; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG PENETRATION; FRONTAL CORTEX; HIPPOCAMPUS; HYPOTHALAMUS; IN VITRO STUDY; MALE; MEDULLA OBLONGATA; NONHUMAN; OCCIPITAL CORTEX; PARIETAL LOBE; PONS; PRIORITY JOURNAL; PROTEIN TRANSPORT; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; THALAMUS; TIGHT JUNCTION;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; CELL LINE, TUMOR; COTININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HIV PROTEASE INHIBITORS; MALE; PERMEABILITY; RATS; RATS, INBRED F344; SAQUINAVIR;

ANIMALIA; RATTUS;

EID: 78650029674     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.07054.x     Document Type: Article

References (77)

1. Abbruscato T. J., Lopez S. P., Mark K. S., Hawkins B. T., and, Davis T. P., (2002) Nicotine and cotinine modulate cerebral microvascular permeability and protein expression of ZO-1 through nicotinic acetylcholine receptors expressed on brain endothelial cells. J. Pharm. Sci. 91, 2525-2538.
2. Agarwal S., Sane R., Gallardo J. L., Ohlfest J. R., and, Elmquist W. F., (2010) Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J. Pharmacol. Exp. Ther. 334, 147-155.
3. Allen D. D., and, Smith Q. R., (2001) Characterization of the blood-brain barrier choline transporter using the in situ rat brain perfusion technique. J. Neurochem. 76, 1032-1041.
4. Allen D. D., Lockman P. R., Roder K. E., Dwoskin L. P., and, Crooks P. A., (2003) Active transport of high-affinity choline and nicotine analogs into the central nervous system by the blood-brain barrier choline transporter. J. Pharmacol. Exp. Ther. 304, 1268-1274.
5. Bachmeier C. J., Spitzenberger T. J., Elmquist W. F., and, Miller D. W., (2005) Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm. Res., 22, 1259-1268.
6. Begley D. J., (2004) ABC transporters and the blood-brain barrier. Curr. Pharm. Des. 10, 1295-1312.
7. Benard A., Bonnet F., Tessier J. F., et al. (2007) Tobacco addiction and HIV infection: toward the implementation of cessation programs. ANRS CO3 Aquitaine Cohort. AIDS Patient Care STDS 21, 458-468.
8. Benowitz N. L., Zevin S., and, Jacob P., III, (1997) Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking. Br. J. Clin. Pharmacol. 43, 259-267.
9. Blasberg R. G., Fenstermacher J. D., and, Patlak C. S., (1983) Transport of alpha-aminoisobutyric acid across brain capillary and cellular membranes. J. Cereb. Blood Flow Metab. 3, 8-32.
10. Burns D. N., Hillman D., Neaton J. D., Sherer R., Mitchell T., Capps L., Vallier W. G., Thurnherr M. D., and, Gordin F. M., (1996) Cigarette smoking, bacterial pneumonia, and other clinical outcomes in HIV-1 infection. Terry Beirn Community Programs for Clinical Research on AIDS. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 13, 374-383.
11. Chen J. L., Wei L., Bereczki D., Hans F. J., Otsuka T., Acuff V., Ghersi-Egea J. F., Patlak C., and, Fenstermacher J. D., (1995) Nicotine raises the influx of permeable solutes across the rat blood-brain barrier with little or no capillary recruitment. J. Cereb. Blood Flow Metab. 15, 687-698.
12. Chen Y., Agarwal S., Shaik N. M., Chen C., Yang Z., and, Elmquist W. F., (2009) P-Glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J. Pharmacol. Exp. Ther. 330, 956-963.
13. Cisternino S., Mercier C., Bourasset F., Roux F., and, Scherrmann J. M., (2004) Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res. 64, 3296-3301.
14. Collier A. C., Tierney C., Downey G. F., et al. (2008) Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV. HIV Clin. Trials 9, 91-102.
15. Cvetkovic M., Leake B., Fromm M. F., Wilkinson G. R., and, Kim R. B., (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27, 866-871.
16. Damaj M. I., Wiley J. L., Martin B. R., and, Papke R. L., (2005) In vivo characterization of a novel inhibitor of CNS nicotinic receptors. Eur. J. Pharmacol. 521, 43-48.
17. Doucette T. A., Ryan C. L., and, Tasker R. A., (2000) Use of osmotic minipumps for sustained drug delivery in rat pups: effects on physical and neurobehavioural development. Physiol. Behav. 71, 207-212.
18. Fairchild C. R., Moscow J. A., O'Brien E. E., and, Cowan K. H., (1990) Multidrug resistance in cells transfected with human genes encoding a variant P-glycoprotein and glutathione S-transferase-pi. Mol. Pharmacol. 37, 801-809.
19. Fitzsimmons M. E., and, Collins J. M., (1997) Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab. Dispos. 25, 256-266.
20. Gaertner L. S., Murray C. L., and, Morris C. E., (1998) Transepithelial transport of nicotine and vinblastine in isolated malpighian tubules of the tobacco hornworm (Manduca sexta) suggests a P-glycoprotein-like mechanism. J. Exp. Biol. 201, 2637-2645.
21. Galai N., Park L. P., Wesch J., Visscher B., Riddler S., and, Margolick J. B., (1997) Effect of smoking on the clinical progression of HIV-1 infection. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 14, 451-458.
22. Gupta A., Zhang Y., Unadkat J. D., and, Mao Q., (2004) HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J. Pharmacol. Exp. Ther. 310, 334-341.
23. Hagenbuch B., and, Gui C., (2008) Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38, 778-801.
24. Hartz A. M., Mahringer A., Miller D. S., and, Bauer B., (2010) 17-beta-Estradiol: a powerful modulator of blood-brain barrier BCRP activity. J. Cereb. Blood Flow Metab. 10, 1742-1755.
25. Hershberger S. L., Fisher D. G., Reynolds G. L., Klahn J. A., and, Wood M. M., (2004) Nicotine dependence and HIV risk behaviors among illicit drug users. Addict. Behav. 29, 623-625.
26. Higgins N., Zingman B. S., Slish J., et al. (2007) Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir. Am. J. Addict. 16, 488-494.
27. Huber J. D., Egleton R. D., and, Davis T. P., (2001) Molecular physiology and pathophysiology of tight junctions in the blood-brain barrier. Trends Neurosci. 24, 719-725.
28. Huisman M. T., Smit J. W., Wiltshire H. R., Hoetelmans R. M., Beijnen J. H., and, Schinkel A. H., (2001) P-Glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol. Pharmacol. 59, 806-813.
29. Huisman M. T., Smit J. W., Wiltshire H. R., Beijnen J. H., and, Schinkel A. H., (2003) Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir. J. Pharmacol. Exp. Ther. 304, 596-602.
30. Hwa Jung B., Chul Chung B., Chung S. J., and, Shim C. K., (2001) Different pharmacokinetics of nicotine following intravenous administration of nicotine base and nicotine hydrogen tartarate in rats. J. Control. Release 77, 183-190.
31. Janneh O., Owen A., Chandler B., Hartkoorn R. C., Hart C. A., Bray P. G., Ward S. A., Back D. J., and, Khoo S. H., (2005) Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. Aids 19, 2097-2102.
32. Janneh O., Hartkoorn R. C., Jones E., Owen A., Ward S. A., Davey R., Back D. J., and, Khoo S. H., (2008) Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. Br. J. Pharmacol. 155, 875-883.
33. Joska J. A., Gouse H., Paul R. H., Stein D. J., and, Flisher A. J., (2010) Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. J. Neurovirol. 2, 101-114.
34. Kamiie J., Ohtsuki S., Iwase R., et al. (2008) Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm. Res. 25, 1469-1483.
35. Katoh M., Suzuyama N., Takeuchi T., Yoshitomi S., Asahi S., and, Yokoi T., (2006) Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. J. Pharm. Sci. 95, 2673-2683.
36. Kim R. B., Fromm M. F., Wandel C., Leake B., Wood A. J., Roden D. M., and, Wilkinson G. R., (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101, 289-294.
37. Kodaira H., Kusuhara H., Ushiki J., Fuse E., and, Sugiyama Y., (2010) Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone. J. Pharmacol. Exp. Ther. 333, 788-796.
38. Lagas J. S., Van Waterschoot R. A., Van Tilburg V. A., Hillebrand M. J., Lankheet N., Rosing H., Beijnen J. H., and, Schinkel A. H., (2009) Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin. Cancer Res. 15, 2344-2351.
39. Letschert K., Faulstich H., Keller D., and, Keppler D., (2006) Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol. Sci. 91, 140-149.
40. Lindl K. A., Marks D. R., Kolson D. L., and, Jordan-Sciutto K. L., (2010) HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J. Neuroimmune Pharmacol. 5, 294-309.
41. Liou H. H., Hsu H. J., Tsai Y. F., Shih C. Y., Chang Y. C., and, Lin C. J., (2007) Interaction between nicotine and MPTP/MPP+ in rat brain endothelial cells. Life Sci. 81, 664-672.
42. Lockman P. R., Roder K. E., and, Allen D. D., (2001) Inhibition of the rat blood-brain barrier choline transporter by manganese chloride. J. Neurochem. 79, 588-594.
43. Lockman P. R., Mumper R. J., and, Allen D. D., (2003) Evaluation of blood-brain barrier thiamine efflux using the in situ rat brain perfusion method. J. Neurochem. 86, 627-634.
44. Lockman P. R., McAfee J. H., Geldenhuys W. J., and, Allen D. D., (2004) Cation transport specificity at the blood-brain barrier. Neurochem. Res. 29, 2245-2250.
45. Lockman P. R., McAfee G., Geldenhuys W. J., Van der Schyf C. J., Abbruscato T. J., and, Allen D. D., (2005a) Brain uptake kinetics of nicotine and cotinine after chronic nicotine exposure. J. Pharmacol. Exp. Ther. 314, 636-642.
46. Lockman P. R., Van der Schyf C. J., Abbruscato T. J., and, Allen D. D., (2005b) Chronic nicotine exposure alters blood-brain barrier permeability and diminishes brain uptake of methyllycaconitine. J. Neurochem. 94, 37-44.
47. Lockman P. R., Gaasch J., McAfee G., Abbruscato T. J., Van der Schyf C. J., and, Allen D. D., (2006) Nicotine exposure does not alter plasma to brain choline transfer. Neurochem. Res. 31, 503-508.
48. Mahringer A., Delzer J., and, Fricker G., (2009) A fluorescence-based in vitro assay for drug interactions with breast cancer resistance protein (BCRP, ABCG2). Eur. J. Pharm. Biopharm. 3, 605-613.
49. Manda V. K., Mittapalli R. K., Geldenhuys W. J., and, Lockman P. R., (2010) Chronic exposure to nicotine and saquinavir decreases endothelial Notch-4 expression and disrupts blood-brain barrier integrity. J. Neurochem. 115, 515-525.
50. Mandula H., Parepally J. M., Feng R., and, Smith Q. R., (2006) Role of site-specific binding to plasma albumin in drug availability to brain. J. Pharmacol. Exp. Ther. 317, 667-675.
51. Martin C., Berridge G., Higgins C. F., Mistry P., Charlton P., and, Callaghan R., (2000) Communication between multiple drug binding sites on P-glycoprotein. Mol. Pharmacol. 58, 624-632.
52. Miller D. S., Nobmann S. N., Gutmann H., Toeroek M., Drewe J., and, Fricker G., (2000) Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol. Pharmacol. 58, 1357-1367.
53. Molla A., Vasavanonda S., Kumar G., et al. (1998) Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 250, 255-262.
54. Mudigonda K., Jukanti R., Apte S. S., Ajjala D. R., Shrivastava W., Kandikere V. N., and, Nirogi R. V., (2006) HPLC quantification of the HIV-1 protease inhibitor saquinavir in brain and testis of mice. Biomed. Chromatogr. 20, 1028-1032.
55. Muenster U., Grieshop B., Ickenroth K., and, Gnoth M. J., (2008) Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions. Pharm. Res. 25, 2320-2326.
56. Nath A., and, Sacktor N., (2006) Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Curr. Opin. Neurol. 19, 358-361.
57. Niaura R., Shadel W. G., Morrow K., Tashima K., Flanigan T., and, Abrams D. B., (2000) Human immunodeficiency virus infection, AIDS, and smoking cessation: the time is now. Clin. Infect. Dis. 31, 808-812.
58. Ohno K., Pettigrew K. D., and, Rapoport S. I., (1978) Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am. J. Physiol. 235, H299-H307.
59. Paoletti P., Fornai E., Maggiorelli F., et al. (1996) Importance of baseline cotinine plasma values in smoking cessation: results from a double-blind study with nicotine patch. Eur. Respir. J. 9, 643-651.
60. Park S., and, Sinko P. J., (2005) P-Glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice. J. Pharmacol. Exp. Ther. 312, 1249-1256.
61. Patlak C. S., Blasberg R. G., and, Fenstermacher J. D., (1983) Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cereb. Blood Flow Metab. 3, 1-7.
62. Perriere N., Yousif S., Cazaubon S., et al. (2007) A functional in vitro model of rat blood-brain barrier for molecular analysis of efflux transporters. Brain Res. 1150, 1-13.
63. Plosker G. L., and, Scott L. J., (2003) Saquinavir: a review of its use in boosted regimens for treating HIV infection. Drugs 63, 1299-1324.
64. Rao P. S., Mallya K. B., Srivenugopal K. S., Balaji K. C., and, Rao U. S., (2006) RNF2 interacts with the linker region of the human P-glycoprotein. Int. J. Oncol. 29, 1413-1419.
65. Shapiro A. B., Fox K., Lam P., and, Ling V., (1999) Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. evidence for a third drug-binding site. Eur. J. Biochem. 259, 841-850.
66. Smit T. K., Brew B. J., Tourtellotte W., Morgello S., Gelman B. B., and, Saksena N. K., (2004) Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J. Virol. 78, 10133-10148.
67. Smith Q. R., (2003) A review of blood-brain barrier transport techniques. Methods Mol. Med. 89, 193-208.
68. Su Y., Zhang X., and, Sinko P. J., (2004) Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol. Pharm. 1, 49-56.
69. Takasato Y., Rapoport S. I., and, Smith Q. R., (1984) An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am. J. Physiol. 247, H484-H493.
70. Wang L., Kittaka M., Sun N., Schreiber S. S., and, Zlokovic B. V., (1997) Chronic nicotine treatment enhances focal ischemic brain injury and depletes free pool of brain microvascular tissue plasminogen activator in rats. J. Cereb. Blood Flow Metab. 17, 136-146.
71. Wang J. S., Markowitz J. S., Donovan J. L., and, Devane C. L., (2005) P-glycoprotein does not actively transport nicotine and cotinine. Addict. Biol. 10, 127-129.
72. Weiss J., Rose J., Storch C. H., Ketabi-Kiyanvash N., Sauer A., Haefeli W. E., and, Efferth T., (2007) Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J. Antimicrob. Chemother. 59, 238-245.
73. Winston A., Mallon P. W., Satchell C., MacRae K., Williams K. M., Schutz M., Law M., Cooper D. A., and, Emery S., (2007) The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation. Clin. Infect. Dis. 44, 1475-1483.
74. Yasui-Furukori N., Uno T., Sugawara K., and, Tateishi T., (2005) Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin. Pharmacol. Ther. 77, 17-23.
75. Yilmaz A., Fuchs D., Hagberg L., Nillroth U., Stahle L., Svensson J. O., and, Gisslen M., (2006) Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study. BMC Infect. Dis. 6, 63.
76. Zlokovic B. V., Begley D. J., and, Chain-Eliash D. G., (1985) Blood-brain barrier permeability to leucine-enkephalin, d-alanine2-d-leucine5-enkephalin and their N-terminal amino acid (tyrosine). Brain Res. 336, 125-132.
77. Zlokovic B. V., Banks W. A., El Kadi H., Erchegyi J., Mackic J. B., McComb J. G., and, Kastin A. J., (1992) Transport, uptake, and metabolism of blood-borne vasopressin by the blood-brain barrier. Brain Res. 590, 213-218.